Biotech Values

[Mufaso]

jbog- So far, it seems to me that what the Chinese have been doing is copying an idea (e.g. T-Cell antibodies, GLP1's) and creating a hundred variations of an idea with or without any real improvement very inexpensively. They are able to quickly run trials in China (especially ph1) and Big Pharma has turned their attention to it purchasing the best ones very cheaply. So far it seems there hasn't been much true innovation- but that appears to be coming.

I agree with a big premise of your post which I think was :

Noting that Chinese companies received $6B of upfront fees in licensing deals in 2024, prominent biotech investor Brad Loncar said that "Last year was just the start of that." “If some kind of protectionism is not put in place, it's going to have a big effect on the future smaller type of companies that exist in the U.S. and their chance of success," he added

Brad Loncar is also part of a very interesting short video on the topic. Here is a link.

𝐎𝐟𝐟 𝐓𝐚𝐫𝐠𝐞𝐭 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: In the first episode of his new podcast, @gline turns the tables on @bradloncar and interviews him about one of the leading topics from this week in SF: China and its potential impact on innovation and M&A.

Full video: https://t.co/YP7njvzAe8 pic.twitter.com/Fq1ttgrlTM

— BiotechTV (@BiotechTV) January 17, 2025

Right now, the biggest impact of Chinese Biotech is that they are getting almost all of the M&A attention. US/European Biotech is definitely going to be facing some new very strong competition in the future.

A lot depends on how fast these companies can do Ex-China trials and if these trials replicate results seen in Chinese only site trials IMO.